Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely ...
Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review ...
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug ...
On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback